UBS Maintains Neutral on 10x Genomics, Raises Price Target to $68
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $68.